Celgene’s Revlimid Patent Escapes IPR Review Sought by Alvogen

The validity of Celgene’s patent 7,968,569 won’t be reviewed by the Patent Trial and Appeal Board, the review board said in a notice posted on its electronic docket.

Alvogen had to prove that it had a “reasonable likelihood” of winning its argument that the patent didn’t cover a new idea and never should have issued.

The patent covers a dosing regimen to treat multiple myeloma, a rare and stubborn blood cancer.

Alvogen argued that it was “standard practice to administer cancer drug therapies in cycles and incorporate rest periods to combat toxicity.”

Celgene defended the validity of its patent and ...